CN111386104A - 一种用于抗病毒感染的药物组合物及制备方法 - Google Patents

一种用于抗病毒感染的药物组合物及制备方法 Download PDF

Info

Publication number
CN111386104A
CN111386104A CN201980005623.9A CN201980005623A CN111386104A CN 111386104 A CN111386104 A CN 111386104A CN 201980005623 A CN201980005623 A CN 201980005623A CN 111386104 A CN111386104 A CN 111386104A
Authority
CN
China
Prior art keywords
weight
pharmaceutical composition
disintegrant
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005623.9A
Other languages
English (en)
Other versions
CN111386104B (zh
Inventor
丁纪钱
陈玮琦
王小雷
刘明健
纪古月
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN111386104A publication Critical patent/CN111386104A/zh
Application granted granted Critical
Publication of CN111386104B publication Critical patent/CN111386104B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种用于抗病毒感染治疗的包含9‑[(R)‑2‑[[(S)‑[[[1‑(异丙氧基羰基)‑1‑甲基]乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的药物组合物及其制备方法和用途，该药物组合物具有稳定性好、流动性好和溶出度高等优点，且在制剂生产过程中无粘冲现象。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201980005623.9A 2018-10-29 2019-10-25 一种用于抗病毒感染的药物组合物及制备方法 Active CN111386104B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811265863.6A CN111096954B (zh) 2018-10-29 2018-10-29 一种用于抗病毒感染的药物组合物及制备方法
CN2018112658636 2018-10-29
PCT/CN2019/113280 WO2020088364A1 (zh) 2018-10-29 2019-10-25 一种用于抗病毒感染的药物组合物及制备方法

Publications (2)

Publication Number Publication Date
CN111386104A true CN111386104A (zh) 2020-07-07
CN111386104B CN111386104B (zh) 2022-09-02

Family

ID=70420131

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811265863.6A Active CN111096954B (zh) 2018-10-29 2018-10-29 一种用于抗病毒感染的药物组合物及制备方法
CN201980005623.9A Active CN111386104B (zh) 2018-10-29 2019-10-25 一种用于抗病毒感染的药物组合物及制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811265863.6A Active CN111096954B (zh) 2018-10-29 2018-10-29 一种用于抗病毒感染的药物组合物及制备方法

Country Status (3)

Country Link
CN (2) CN111096954B (zh)
TW (1) TWI827715B (zh)
WO (1) WO2020088364A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113501846A (zh) * 2021-06-10 2021-10-15 江苏豪森药业集团有限公司 艾美酚胺替诺福韦半富马酸复合物、晶型及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105399771A (zh) * 2014-07-21 2016-03-16 连云港宏创药业有限公司 替诺福韦前药晶型及其制备方法和用途
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4070787T (pt) * 2015-06-30 2023-05-22 Gilead Sciences Inc Formulações farmacêuticas
ES2757560T3 (es) * 2015-11-09 2020-04-29 Gilead Sciences Inc Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105399771A (zh) * 2014-07-21 2016-03-16 连云港宏创药业有限公司 替诺福韦前药晶型及其制备方法和用途
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113501846A (zh) * 2021-06-10 2021-10-15 江苏豪森药业集团有限公司 艾美酚胺替诺福韦半富马酸复合物、晶型及其制备方法和应用

Also Published As

Publication number Publication date
TW202034904A (zh) 2020-10-01
TWI827715B (zh) 2024-01-01
CN111096954B (zh) 2022-09-16
CN111386104B (zh) 2022-09-02
WO2020088364A1 (zh) 2020-05-07
CN111096954A (zh) 2020-05-05

Similar Documents

Publication Publication Date Title
US9549941B2 (en) Compositions and methods for treating hepatitis C virus
CA2856529C (en) Compositions and methods for treating hepatitis c virus
JP2021167343A (ja) パルボシクリブの固形剤形
CN105646584B (zh) 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
US20070172521A1 (en) Levetiracetam formulations and methods for their manufacture
CN111386104B (zh) 一种用于抗病毒感染的药物组合物及制备方法
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
CN113633616A (zh) 一种生物利用度高的固体制剂
CN115461052B (zh) Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
CN110917197A (zh) 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
CN105367551A (zh) 达比加群酯乙醇酸盐及其制备方法和应用
Shanmugam et al. Formulation and evaluation of sustained release matrix tablet of Zidovudine using different polymers
EP3470062B1 (en) Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
CN112057430A (zh) 一种泛昔洛韦药物组合物
US20070026077A1 (en) Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
CN105348261A (zh) 达比加群酯丙酮酸盐及其制备方法和应用
CN106580909B (zh) 一种含有盐酸沙格雷酯固体药物组合物
CN117338733B (zh) 一种富马酸替诺福韦二吡呋酯片及其制备工艺
CN105440017A (zh) 达比加群酯香草酸盐及其制备方法和应用
TWI814468B (zh) 藥用組合物、其製備方法及用途
CN105348260A (zh) 达比加群酯氢溴酸盐及其制备方法和应用
CN117338733A (zh) 一种富马酸替诺福韦二吡呋酯片及其制备工艺
CN115120596A (zh) 一种喹唑啉化合物及药物组合物的应用
WO2023172958A1 (en) Stable formulations of talabostat
CN117357531A (zh) 一种药物组合物、其制备方法和其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029602

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant